PCT translation errors in China can permanently affect patent scope. This guide explains what can be corrected, when, and how the PCT and Paris routes differ.
Sarah had 31 months from her priority date and a PCT application that hadn't been reviewed for Chinese-specific risk. Peter Lin walks through the 45 days they worked together — and the four lessons every foreign inventor should take from it.
A translation error in your PCT Chinese application can silently narrow the scope of your patent — sometimes permanently. Peter Lin explains how CNIPA handles correction requests, what the standard really is, and why prevention matters far more than remedy.
A US Provisional Patent Application (PPA) is a smart starting move — but using it as the priority basis for China requires getting three specific details right. Peter Lin explains what goes wrong when founders skip these steps.
Many applicants entering China via PCT pay significantly more than they need to. Not because the fees are unavoidable — but because nobody walked them through the levers that exist. Peter Lin outlines a straightforward approach to reducing China patent costs without sacrificing meaningful protection.
Amending claims when you enter China's national phase via PCT sounds straightforward — but CNIPA applies strict "no new matter" rules that trip up many applicants. Peter Lin explains what's actually permitted, what gets rejected, and how to amend smartly.
When you enter China's national phase via PCT, a set of costs gets locked in based on decisions you made months or years earlier. Peter Lin explains what drives those costs — and how to structure your PCT application to avoid unnecessary expense before you even start prosecution.
Twelve months. Thirty months. These two deadlines define your entire China patent window — and confusing them can cost you rights you can never recover. Peter Lin breaks down exactly what happens at each deadline and how to use both strategically.
Both the Paris Convention and PCT let you claim priority when filing in China — but the rules, deadlines, and strategic implications are very different. Peter Lin explains the one distinction that can make or break your China filing.
Most inventors file a PCT application with broad claims — then arrive at China's national phase unprepared for the cost and complexity. Peter Lin explains the "slimming strategy": a focused, cost-effective way to enter China via PCT that protects what matters most.
